Article Per Year (5 Year)
p-Index From 2021 - 2026
0.751
P-Index
This Author published in this journals
All Journal Majalah Farmaseutik Indonesian Journal of Medicine Journal Syifa Sciences and Clinical Research (JSSCR) Medfarm: Jurnal Farmasi dan Kesehatan
Candraningrat, I Dewa Agung Ayu Diva
Unknown Affiliation
Chemistry Medicine & Pharmacology Public Health

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

 1 
Evaluasi Penggunaan Antibiotik pada Community Acquired Pneumonia Candraningrat, I Dewa Agung Ayu Diva; Andayani, Tri Murti; Sari, Ika Puspita
Majalah Farmaseutik Vol 20, No 4 (2024)
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/farmaseutik.v20i4.92448

Abstract

Community Acquired Pneumonia (CAP) merupakan infeksi yang terjadi di paru-paru yang didapatkan dari komunitas dan sering meningkatkan angka rawat inap di rumah sakit. Bakteri yang paling umum menjadi penyebab CAP adalah Streptococcus pneumoniae, Mycoplasma pneumoniae, dan Chlamydophila pneumoniae. Berdasarkan pada pedoman American Thoracic Society (ATS) dan Infectious Disease Society of America (IDSA), penggunaan terapi antibiotik pada pasien CAP dinilai berdasarkan stabilitas klinisnya. Ulasan artikel ini bertujuan untuk membandingkan hasil evaluasi penggunaan antibiotic yang dilihat dari stabilitas klinis dan keamanannya. Ulasan artikel bertujuan untuk membandingkan hasil penelitian yang diperoleh dari PubMed sebagai literatur dan diagram PRISMA sebagai guideline pada proses seleksi artikel. Berdasarkan hasil ulasan artikel diperoleh 10 artikel yang sesuai dengan topik dan tujuan. Dapat disimpulkan bahwa penggunaan antibiotik golongan betalaktam atau fluorokuinolon memiliki efikasi dan keamanan yang baik untuk pasien CAP
Effect of Hydroxypropyl Methylcellulose Concentration Variations as a Gelling Agent on the Physical Quality of Hydrogel Formulations Containing Ethanol Extract of Impatiens balsamina L. Herb Buana, Komang Dirga Mega; Pebriani, Ni Luh Gede Wiwin; Suryani, Ade Irma; Mendra, Ni Nyoman Yudianti; Candraningrat, I Dewa Agung Ayu Diva; Sasadara, Maria Malida Vernandes
Indonesian Journal of Medicine Vol. 10 No. 4 (2025)
Publisher : Masters Program in Public Health, Universitas Sebelas Maret, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.26911/theijmed.2025.10.4.872

Abstract

Background: Impatiens balsamina L. herb is known to possess anti-inflammatory and antioxidant activities, making it a promising candidate for development as an active ingredient in topical formulations. Hydrogels are considered an ideal delivery system for topical wound treat­ment due to their ability to provide controlled drug release, with hydroxypropyl methyl­cellulose (HPMC) commonly employed as a stable gelling agent. This study aimed to evaluate the effect of varying HPMC concentrations on the physical quality of hydrogel formulations containing ethanol extract of Impatiens balsamina L. herb. Subjects and Method: This was an experimental study. Hydrogel formulations were prepared with varying concentrations of hydroxypropyl methylcellulose (HPMC) at 1%, 2%, and 3% as the gelling agent. Each formulation was evaluated for physical quality parameters, including organo­leptic properties, homogeneity, spreadability, adhesiveness, and pH value, following standard topical formulation testing procedures. Results: The evaluation results showed that all formulations exhibited good homogeneity and pH values within the safe range for skin application. Increasing HPMC concentration did not visually affect the color of the formulations; however, it influenced the formulation consistency, decreased spreadability, and increased adhesiveness. Conclusion: Variations in HPMC concentration in hydrogel formulations containing ethanol extract of Impatiens balsamina L. herb significantly affected the physical quality parameters, particularly consistency, spreadability, and adhesiveness. The formulation with 2% HPMC concen­tration demonstrated the most optimal physical characteristics for topical application.
Clinical Outcomes of Antihypertensive Therapy in Chronic Kidney Disease: A Literature Review Candraningrat, I Dewa Agung Ayu Diva; Ayu Sri Handani, Dewa; Vyra Ginanti Putri, Ni Putu; Dirga Mega Buana, Komang
Journal Syifa Sciences and Clinical Research Vol 7, No 3 (2025): Volume 7 Number 3 2025
Publisher : State University of Gorontalo

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37311/jsscr.v7i3.34331

Abstract

Chronic kidney disease (CKD) carries high cardiovascular risk, and optimal antihypertensive therapy is central to slowing progression. This review synthesized randomized controlled trials from the past 10 years in adults with CKD identified via PubMed, focusing on estimated glomerular filtration rate (eGFR) decline, albumin/protein excretion, and cardiovascular outcomes; study selection followed PRISMA. Renin–angiotensin system inhibitors (RASi) consistently lowered blood pressure, reduced albumin/protein excretion, and attenuated eGFR decline versus comparators. In a crossover trial, azilsartan produced greater reductions in urine protein-to-creatinine ratio and faster blood-pressure control than candesartan. Among calcium channel blockers, benidipine (T/L-type) decreased urinary albumin excretion and improved vascular surrogates versus amlodipine (L-type), suggesting class-specific renal effects. Nifedipine GITS combined with candesartan improved blood-pressure control in high-risk subgroups. Adding spironolactone can further reduce albuminuria but increases hyperkalemia risk; co-administration of patiromer enables RASi/MRA intensification under biochemical monitoring. Overall, RASi remain first-line—particularly in albuminuric CKD—while selected combinations with a dihydropyridine calcium channel blocker or a mineralocorticoid receptor antagonist (with a potassium binder when needed) may augment renoprotection. Treatment should be individualized to CKD stage, comorbidities, and laboratory follow-up.
Cost Minimization Analysis of Antibiotic Drug Use in Pneumonia Patients at Udayana Class II Hospital Wiryani, Luh Santhi Utami; Megawati, Fitria; Candraningrat, I Dewa Agung Ayu Diva
MEDFARM: Jurnal Farmasi dan Kesehatan Vol 14 No 2 (2025): Medfarm: Jurnal Farmasi dan Kesehatan
Publisher : LPPM Akafarma Sunan Giri Ponorogo

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.48191/medfarm.v14i2.655

Abstract

Pneumonia is one of the leading causes of morbidity and mortality in Indonesia, with a high economic burden mainly due to antibiotic use, which consumes a large portion of hospital budgets. This study aimed to analyze the cost-minimization of antibiotic therapy in hospitalized pneumonia patients at Tk II Udayana Hospital. A descriptive non-experimental retrospective study was conducted using medical records of pneumonia inpatients at Tk.II Udayana Hospital from January to December 2023. A total of 138 patients met the inclusion criteria. Data analyzed included demographics, length of stay, and direct medical costs. Cost minimization analysis was performed by comparing the average direct medical costs of each antibiotic therapy. Of 233 medical records screened, only 138 fulfilled the criteria. Male patients (53.6%) were slightly more than females (46.4%), with the majority aged 1–5 years (64.5%). Most patients had a length of stay of 1–7 days (99.3%). Antibiotics used included Ceftriaxone, Cefotaxime, Azithromycin, Cefoperazone, and Cefixime (monotherapy or combination). The highest direct medical cost was found in Ceftriaxone monotherapy (IDR 1,973,061 ± 393,521), while the lowest was in Cefixime monotherapy (IDR 1,574,659 ± 39,208). Statistical analysis using the Mann-Whitney test showed no significant difference in costs based on the length of stay (p=0.123). Cefixime monotherapy was the most cost-minimization therapy for pneumonia inpatients at Tk.II Udayana Hospital, with equal clinical effectiveness but lower costs compared to other therapies. This finding may serve as a consideration for hospital formulary development to improve budget efficiency without compromising quality of care.
Co-Authors Ade Irma Suryani Ayu Sri Handani, Dewa Buana, Komang Dirga Mega Dirga Mega Buana, Komang Ika Puspita Sari Megawati, Fitria Mendra, Ni Nyoman Yudianti Pebriani, Ni Luh Gede Wiwin Sasadara, Maria Malida Vernandes Tri Murti Andayani Vyra Ginanti Putri, Ni Putu Wiryani, Luh Santhi Utami